Unique Research Funding Strategy
Cure Alzheimer’s Fund (CAF) takes a venture capital approach to medical research by finding the visionaries in the field, supporting them, focusing on the essentials by establishing a frugal culture and daring to be great. Our research objective is to support the scientists doing the most innovative work that will move knowledge of Alzheimer’s pathology most expeditiously to prevention and cure.
Our research follows a Research Roadmap designed by leading Alzheimer’s researchers who form the CAF Research Consortium. Proposals typically arise from members of the Consortium for their own work or complementary projects with or by others. Proposals are brief, with an emphasis on objectives, proposed outcomes, method and supporting data. They are reviewed by the chair of our Research Consortium and then by members of the Scientific Advisory Board. No scoring rubric is used; rather, questions or concerns are related to the researcher, who then may modify or explain the proposal accordingly. Mid-year and final reports are required. With sufficient reason to continue, some projects may be funded beyond one year. We do not accept unsolicited proposals, nor do we fund indirect costs or overhead at host institutions. Approval usually takes about two weeks, with funds delivered to the host institution within three weeks.
Latest Research Updates
A new "alternative amyloid hypothesis” from the lab of Dr. Charles Glabe, at the University of California at Irvine, helps explain precisely how neurons (nerve cells) die in Alzheimer’s disease and how known genetic mutations initiate a chain reaction in this long process. The important new hypothesis was driven by research supported by Cure Alzheimer’s Fund, and has just been being published in the Journal Neurobiology of Disease. Dr.
A promising first-in-class drug stimulates the creation of new nerve cells in the brains of Alzheimer's mice and will soon be tested in the brains of human patients, thanks to new research by Dr. Sam Gandy, member of Cure Alzheimer's Fund's Research Consortium, at Mount Sinai School of Medicine in New York.
The world already is very familiar with both Alzheimer’s disease (AD), primarily a disease that occurs in the elderly, and Down syndrome (DS), a genetic condition present at birth. What many don’t realize is that these two conditions also overlap. By age 40, nearly all people born with Down syndrome have begun accruing the plaque and tangle hallmarks of Alzheimer’s. By age 60, most exhibit signs of dementia.
Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).
A new blood test, which has the potential to accurately diagnose Alzheimer’s disease in individuals and significantly advance drug testing and research on the disease, has been developed through grant funding by Cure Alzheimer's Fund.
The test, known as Immunosignature (IS) and developed by a team led by UCLA neurologist Lucas Restrepo, uses a special method of fluorescent tagging of antibodies in the blood to recognize an identifiable binding pattern—or antibody "signature"—associated with Alzheimer's.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.